CORT · Corcept Therapeutics Inc
Price
Snapshot
50 fields · last close| Market Cap | $11.92B |
| P/E | 216.05 |
| Float | 95.40M |
| Beta | 0.50 |
| Volatility | 12.6% |
| Exchange | NASDAQ |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 56 |
| Price | 116.28 |
| Change | +5.43% |
| Prev Close | 110.29 |
| Open | 116.80 |
| Day Low | 108.41 |
| Day High | 117.90 |
| Avg Vol | 3 |
| Avg $ Vol | $283.0M |
| 52W High | 126.38 |
| 52W Low | 28.66 |
| 52W Pos | 89.7% |
| From High | −7.99% |
| From Low | +305.72% |
| Max DD 1Y | −64.40% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +1.19% |
| SMA 50 | +7.51% |
| SMA 200 | +70.01% |
| RSI (14) | 46.6 |
| Vol 30D | 32.0% |
| Vol 90D | 60.6% |
| 1Y Range | 29–126 |
| Daily bars | 516 |
| Perf Week | −2.22% |
| Perf Month | −7.33% |
| Perf Quarter | +38.02% |
| Perf Half Y | +223.62% |
| Perf Year | +46.70% |
| Perf YTD | +204.40% |
| Prev Day | +5.43% |
| Clavix | C- |
| Debt / Eq | 0.00 |
| Curr Ratio | 2.92 |
| Int Cover | 19.8× |
| FCF Margin | 16.3% |
| Rev Growth | +31.7% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 14 / 14 |
Clavix risk grade
regraded every trading dayCORT grades C-, 56 of 100. Steadiest on Sector Resilience (68), most exposed on Price Stability (42, fragile). 1 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 14 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| CORT | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.50 | 0.43 |
| Volatilityannualized | 12.6% | 10.8% |
| Max drawdown, past yearworst peak-to-trough fall | −64.4% | — |
| Typical daily movemedian absolute daily change | 1.62% | — |
| Days beyond ±3%of the last 252 sessions | 7128% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| CORT | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.50 | 0.43 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| CORT | |
|---|---|
| 1 week | −2.2% |
| 1 month | −7.3% |
| Year to date | +204.4% |
| 1 year | +46.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| CORT | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 25since 28 Jul |
| Average score0 most bearish, 100 most bullish | 65 |
| Bullish · bearisharticles above 60 · below 40 | 19 · 6 |
| Directionarticles whose tone is improving vs worsening | 19 ↑ 6 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| CORT | |
|---|---|
| Revenue growthyear over year | +31.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openCorcept's drug Lifyorli, when given together with the chemotherapy nab-paclitaxel, received a positive opinion from the CHMP (the European Medicines Agency's main review committee) for treating ovarian cancer that has stopped responding to platinum-based chemotherapy. A final approval decision from the European Commission is expected in the fourth quarter of 2026.
Stock analysts at Zacks Research raised their earnings estimate for Corcept Therapeutics' fourth quarter of 2026 in a report issued on September 16th. The article body is truncated and does not include the specific forecast figure.
Corcept's Korlym sales grew 6.2% in the first half of 2026, driven by rising demand. The article also notes that the launch of Lifyorli gives the company a way to bring in revenue from additional products.
Corcept's main drug Korlym saw sales rise 6.2% in the first half of 2026 on growing demand, and the company has launched a second product called Lifyorli to bring in new revenue.
Manulife (The Manufacturers Life Insurance Company) opened a new position in Corcept Therapeutics during the second quarter, buying 30,914 shares worth about $2.69 million, according to its most recent SEC 13F filing.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ELAN | Elanco Animal Health Inc | B- | $11.20B | — | 1.76 | Compare |
| AXSM | Axsome Therapeutics Inc | B | $10.88B | — | 0.81 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $15.63B | 16.61 | 0.38 | Compare |
| CRNX | Crinetics Pharmaceuticals Inc | — | $9.01B | — | 0.45 | Compare |
| VTRS | Viatris Inc | B+ | $20.71B | — | 0.91 | Compare |
| MANE | Veradermics Inc | D- | $4.46B | — | -0.10 | Compare |
| ZTS | Zoetis Inc | B | $31.87B | 11.28 | 0.70 | Compare |
| RPRX | Royalty Pharma PLC | A | $33.59B | 41.21 | 0.39 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.